Paris, June 14, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, as part of the development of its first drug candidate ACT017 who has just successfully completed a phase 1 study in the healthy volunteer, confided to Simbec-Orion carrying out his […]
Press Releases
June 14, 2018
ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE
April 25, 2018
ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE
Paris, April 25th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, has discussed with the European Medicines Agency (EMA) the development of its drug candidate, ACT017. This meeting follows the completion of the first-in-human study in January 2018 which provided preliminary […]
February 5, 2018
ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS
Paris, February 5th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announced today the completion of its phase I clinical trial in healthy volunteers with its drug candidate, ACT017. ACT017 is a humanized monoclonal antibody fragment (Fab) […]
January 20, 2018
Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital
Paris, January 4th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the closing of an equity financing led by Primer Capital. The financing round includes investments in equity from Primer Capital and historical shareholders Anaxago, […]
January 20, 2018
Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer
Paris, December 20th, 2017 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the appointment of Dr Yannick Plétan as Chief Medical Officer. He will report to Gilles Avenard, CEO of Acticor Biotech and be responsible for […]
October 18, 2017
Acticor Biotech first-in-human clinical trial in healthy volunteers
Paris, October 17th, 2017 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and myocardial infarction, today announced the agreement of Dutch Authorities for the initiation of a phase I clinical trial in healthy volunteers with its drug candidate, ACT017. ACT017 is a humanized fragment of […]